Healthcare Industry News: Alzheimer's
News Release - August 21, 2007
EPIX Pharmaceuticals Appoints Margaret Uprichard, Pharm.D. as Senior Vice President, Regulatory Affairs & Quality
LEXINGTON, Mass.--(HSMN NewsFeed)--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX ) today announced that Margaret Uprichard, Pharm.D., has been appointed to the position of senior vice president, regulatory affairs and quality for the company. In this role, Dr. Uprichard will be responsible for leading all regulatory affairs activities for the company, including developing and maintaining effective regulatory strategies for EPIX's four lead product candidates currently in clinical trials."We are extremely pleased to welcome Dr. Uprichard to our team. Her extensive drug development background and deep regulatory experience will provide experienced counsel and further momentum for our rapidly expanding clinical programs," said Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX. "As we continue to move toward our goal of providing novel products to address areas of high unmet medical need, effective regulatory affairs strategies will continue to be a critical component of our program."
Dr. Uprichard joins EPIX from Point Therapeutics, where she most recently served as senior vice president, chief development officer and was responsible for leading the company's drug development activities. Prior to her tenure at Point Therapeutics, she served as director, clinical research for the oncology and rheumatology/immunology divisions of Pfizer, where she also focused on central nervous system diseases. Dr. Uprichard was involved in the development and approval of tacrine (Cognex®), the first approved agent for Alzheimer's disease. In her role in regulatory affairs at Pfizer, she had responsibility for oncology and cardiovascular products and played an integral role in both the IND and NDA submissions of several of the company's products, including Lipitor®. Dr. Uprichard received her doctoral degree from the University of Michigan and continues to hold an academic appointment as clinical assistant professor of pharmacy.
"I am thrilled to join the EPIX team and look forward to advancing the company's regulatory strategies to move our lead candidates through the clinical process even more efficiently," said Dr. Uprichard.
About EPIX
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics and Bayer Schering Pharma AG, Germany. For more information, please visit the company's website at www.epixpharma.com.
This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on current expectations of management. These statements relate to, among other things, our expectations regarding the future development of our drug candidates. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.
Source: EPIX Pharmaceuticals
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
